These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 9337444)

  • 21. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
    Walsh TJ; Hiemenz JW; Seibel NL; Perfect JR; Horwith G; Lee L; Silber JL; DiNubile MJ; Reboli A; Bow E; Lister J; Anaissie EJ
    Clin Infect Dis; 1998 Jun; 26(6):1383-96. PubMed ID: 9636868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review.
    Rowles DM; Fraser SL
    Clin Infect Dis; 1999 Dec; 29(6):1564-5. PubMed ID: 10585814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.
    Wasan KM; Kennedy AL; Cassidy SM; Ramaswamy M; Holtorf L; Chou JW; Pritchard PH
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3146-52. PubMed ID: 9835506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of the lipid formulations of amphotericin B.
    Dupont B
    J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
    Zhang Z; Diener RM; Lipman JM
    Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.
    Linden P; Williams P; Chan KM
    Clin Transplant; 2000 Aug; 14(4 Pt 1):329-39. PubMed ID: 10945204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate.
    Garnacho-Montero J; Ortiz-Leyba C; García Garmendia JL; Jiménez Jiménez F
    Clin Infect Dis; 1998 Apr; 26(4):1016. PubMed ID: 9564508
    [No Abstract]   [Full Text] [Related]  

  • 30. Amphotericin B lipid complex: in visceral leishmaniasis.
    Goldsmith DR; Perry CM
    Drugs; 2004; 64(17):1905-11; discussion 1912-3. PubMed ID: 15329037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of renal safety in amphotericin B lipid complex-treated patients.
    Alexander BD; Wingard JR
    Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amphotericin B lipid complex for the treatment of invasive fungal infections.
    Linden PK
    Expert Opin Pharmacother; 2003 Nov; 4(11):2099-110. PubMed ID: 14596663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients.
    Herbrecht R; Auvrignon A; Andrès E; Guillemain R; Suc A; Eyer D; Pailler C; Letscher-Bru V; Leverger G; Schaison G
    Eur J Clin Microbiol Infect Dis; 2001 Feb; 20(2):77-82. PubMed ID: 11305476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
    Winston DJ; Schiller GJ
    Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
    [No Abstract]   [Full Text] [Related]  

  • 35. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats.
    Bhamra R; Sa'ad A; Bolcsak LE; Janoff AS; Swenson CE
    Antimicrob Agents Chemother; 1997 May; 41(5):886-92. PubMed ID: 9145839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis.
    Capilla J; Clemons KV; Sobel RA; Stevens DA
    J Antimicrob Chemother; 2007 Sep; 60(3):673-6. PubMed ID: 17646202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amphotericin B-associated hyperbilirubinemia: case report and review of the literature.
    Olin JL; Spooner LM
    Pharmacotherapy; 2006 Jul; 26(7):1011-7. PubMed ID: 16878370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of newer antifungal therapies in clinical practice: what do the data tell us?
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antifungals and renal safety--getting the balance right.
    Saliba F
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():21-4. PubMed ID: 16704922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of fungal infections with ABLC in the home-care setting.
    Weissmann AC
    J Assoc Nurses AIDS Care; 1999; 10(3):43-52. PubMed ID: 10707695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.